Incyte Corporation (Nasdaq: INCY) today announced that the U.S. Food and
Drug Administration (FDA) has approved Jakafi ® (ruxolitinib)
for the treatment of patients with polycythemia vera (PV) who have had
an inadequate response to or are intolerant of hydroxyurea.
Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and
Drug Administration (FDA) has expanded the existing indication for
REVLIMID ® (lenalidomide) in combination with dexamethasone to
include patients newly diagnosed with multiple myeloma (NDMM). REVLIMID
plus dexamethasone was previously approved in June 2006 for use in
multiple myeloma patients who have received at least one prior therapy.
SOUTH SAN FRANCISCO, Calif., March 2, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA) today announced that its collaborative partner, Memorial Sloan Kettering Cancer Center (MSK) has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) for Atara's optioned cytotoxic T lymphocytes activated against Epstein-Barr Virus (EBV-CTL) in the treatment of patients with rituximab-refractory, EBV-associated lymphoproliferative disease (EBV-LPD), a type of malignancy occurring after allogeneic hematopoietic cell transplantation (HCT). Allogeneic HCT is also commonly called a bone marrow transplant.
bluebird bio, Inc. (Nasdaq:BLUE) a clinical-stage company committed to
developing potentially transformative gene therapies for severe genetic
and rare diseases, today announced that the U.S. Food and Drug
Administration (FDA) has granted Breakthrough Therapy designation to
LentiGlobin ® BB305 Drug Product for the treatment of
transfusion-dependent patients with beta-thalassemia major.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) today announced that the U.S.
Food and Drug Administration (FDA) has granted conditional approval for
an Investigational Device Exemption (IDE) for a pivotal clinical trial,
named the ‘STAR’ trial, to evaluate Cytori Cell Therapy™ as a potential
treatment for impaired hand function in scleroderma, a rare autoimmune
disease affecting approximately 50,000 patients in the United States.
Alexion Pharmaceuticals, Inc. (Nasdaq:ALXN) announced today that the
U.S. Food and Drug Administration (FDA) has accepted for Priority Review
the Company’s Biologics License Application (BLA) for asfotase alfa, an
investigational, first-in-class enzyme replacement therapy for treatment
of patients with infantile- and juvenile-onset hypophosphatasia (HPP).
The BLA submission is supported by data from 71 treated patients with
HPP enrolled in three prospective studies and their extensions, as well
as two retrospective natural history studies.
Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX)
today confirmed that the U.S. Food and Drug Administration (FDA) has
granted seven years of market exclusivity in the U.S. to Ryanodex ®
(dantrolene sodium) for Injectable Suspension for the treatment of
malignant hyperthermia (MH). Ryanodex was designated an orphan drug in
August 2013 and was approved by the FDA in July 2014 for this indication.
Generic biotech drugs took one step close to reality after a Food and Drug Administration advisory panel recommended the agency approve a Novartis AG (NVS) version of Amgen's Inc.'s (AMGN) drug Neupogen, according to media reports late Wednesday.
Edison International, the parent company of Southern California Edison
(SCE), reminds high school seniors that there’s still time to apply for
the 2014-15 Edison
Scholars Program , which offers $1.2 million in scholarships to high
school seniors planning to pursue college studies in science,
technology, engineering or math ( STEM )
MOUNTAIN VIEW, CA--(Marketwired - February 13, 2015) - Today eHealth, Inc. (NASDAQ: EHTH) ( eHealth.com ), the nation's first and largest private online health insurance exchange, released updated Price Index figures showing what last-minute health insurance shoppers are paying on average for health insurance.
Sign-up for February 15 Is the Last Day of Open Enrollment: As Deadline Approaches, Last-Minute Shoppers Are Paying an Average Premium of $273 per Month for Individual Health Insurance Coverage investment picks
By Greg Robb, MarketWatch
WASHINGTON (MarketWatch) -- Federal Reserve Chairwoman Janet Yellen said Fed staff should "feel safe" to speak up about problems they uncover at the nation's biggest banks and not fear upsetting any relationship between the U.S. central bank and the industry.
By Ryan Tracy and Scptt Patterson
WASHINGTON--Regulators on Thursday handed Wall Street banks a temporary reprieve they have been clamoring for from a rule that forces them to pull out of certain risky investments.
By Greg Robb, MarketWatch
$22,000 per month for life in one retirement payment
WASHINGTON (MarketWatch) -- Allan Landon, a former chief executive of Bank of Hawaii Corp., was tapped early this month for a seat on the Federal Reserve Board mainly to represent smaller community banks, which have felt left out in deliberations about post-financial-crisis regulations.
By Pedro Nicolaci da Costa
Widespread manipulation of key benchmark interest rates such as the London Interbank Offered Rate, or Libor, threatens public confidence in the financial system, and must be prevented through fines and criminal prosecution, Federal Reserve Gov.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.